The two companies leverage combined expertise in therapeutics and in diagnostics to improve patient care
Nachrichten
bioMérieux receives De Novo FDA Authorization for its BIOFIRE® Joint Infection (JI) Panel
04 Mai, 2022Joint infections (“septic arthritis”) are serious infections involving either native or prosthetic joints. They are medical emergencies which can occur at all ages, and can lead to functional joint impairment, long-lasting disability, and may even be life-threatening. The number of prosthetic...
bioTheranostics’ Breast Cancer IndexSM predicts risk for late recurrence in early stage ER-positive breast cancer patients
10 Dezember, 2010
bioTheranostics, a bioMérieux company that develops innovative oncology diagnostic tests to support targeted disease management, announced today new findings from a clinical study evaluating the company’s Breast Cancer Index (BCI) molecular oncology test. Data from the study were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).
bioMérieux Introduces Revolutionary LockSure® Plate Technology
07 September, 2010
Lab Informatics Expert Joins bioMérieux
19 Juli, 2010
A world leader in in vitro diagnostics, bioMérieux today announced the appointment of Jacques L. Baudin as Vice President, Commercial Operations Information Technology.
Data from Clinical Studies of bioTheranostics’ CancerTYPE ID® and Breast Cancer Index® Molecular Oncology Tests Presented at ASCO 2010 Annual Meeting*
06 Juni, 2010
bioTheranostics, a bioMérieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company’s CancerTYPE ID® and Breast Cancer Index® molecular oncology tests. Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago.